(Q47422556)

16 January 2018

meta-analysis

0 references

title

Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development (English)

1 reference

16 January 2018

1 reference

1 reference

I Demin

1

1 reference

16 January 2018

B Hamrén

2

1 reference

16 January 2018

O Luttringer

3

1 reference

16 January 2018

G Pillai

4

1 reference

16 January 2018

T Jung

5

1 reference

16 January 2018

language of work or name

English

0 references

publication date

4 July 2012

1 reference

16 January 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

16 January 2018

volume

92

1 reference

16 January 2018

issue

3

1 reference

16 January 2018

page(s)

352-359

1 reference

16 January 2018

https://scigraph.springernature.com/pub.10.1038/clpt.2012.69

exact match

0 references

cites work

Model-based drug development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

Treatment of rheumatoid arthritis: state of the art 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

Disease progression meta-analysis model in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

Rheumatoid arthritis market

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

inferred from DOI database lookup

7 January 2021

based on heuristic

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.69

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2012.69

1 reference

16 January 2018

Dimensions Publication ID

1033821019

0 references

1 reference

16 January 2018